Savara Inc (SVRA) Receives $24.75 Average Price Target from Analysts

Shares of Savara Inc (NASDAQ:SVRA) have been given a consensus rating of “Hold” by the seven analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $24.75.

Several research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Thursday, September 13th. HC Wainwright reiterated a “buy” rating on shares of Savara in a research note on Thursday, November 8th. BidaskClub lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Friday, November 30th. Finally, ValuEngine lowered shares of Savara from a “hold” rating to a “sell” rating in a research note on Wednesday, November 21st.

In other Savara news, CFO David L. Lowrance sold 18,480 shares of the stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $9.22, for a total transaction of $170,385.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert N. Neville bought 23,517 shares of the firm’s stock in a transaction on Friday, December 21st. The shares were acquired at an average price of $6.38 per share, for a total transaction of $150,038.46. Following the transaction, the chief executive officer now owns 498,028 shares in the company, valued at $3,177,418.64. The disclosure for this purchase can be found here. Corporate insiders own 6.10% of the company’s stock.

Several large investors have recently made changes to their positions in SVRA. Metropolitan Life Insurance Co. NY acquired a new position in shares of Savara during the 2nd quarter worth approximately $104,000. Alliancebernstein L.P. acquired a new position in shares of Savara during the 3rd quarter worth approximately $118,000. MetLife Investment Advisors LLC acquired a new position in shares of Savara during the 2nd quarter worth approximately $148,000. Engineers Gate Manager LP acquired a new position in shares of Savara during the 3rd quarter worth approximately $198,000. Finally, Rhumbline Advisers acquired a new position in shares of Savara during the 2nd quarter worth approximately $270,000. Hedge funds and other institutional investors own 51.14% of the company’s stock.

NASDAQ:SVRA traded down $0.04 on Friday, hitting $7.70. 4,545 shares of the company’s stock were exchanged, compared to its average volume of 262,536. The company has a debt-to-equity ratio of 0.10, a current ratio of 10.23 and a quick ratio of 10.23. Savara has a 52 week low of $6.21 and a 52 week high of $14.06. The stock has a market capitalization of $277.17 million, a PE ratio of -4.31 and a beta of 0.26.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, analysts anticipate that Savara will post -1.42 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Further Reading: Day Trading – Risk Worth the Reward?

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply